Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 and KL-A167 With or Without Chemotherapy in Advanced or Metastatic NSCLC
NCT05351788Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- May 2022
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Kelun-Biotech. Primary endpoints: Incidence and severity of adverse events at 24 months and Objective Response Rate at 24 months. Started May 2022; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05351788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351788.